Skip to main content

Table 2 Effectiveness of first-line antiretroviral therapy at 6, 12, and 24 months from start of antiretroviral therapy (ART) stratified by regimen and calendar year

From: Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil

  

6 months

12 months

24 months

Overall

 

N (%)

N (%)

N (%)

 

For patients with HIV VL

754/980 (76.9)

802/1054 (76.1)

637/938 (67.9)

 

Best-case scenarioa

1085/1311 (82.8)

1059/1311 (80.8)

1010/1311 (77.0)

 

Worst-case scenariob

754/1311 (57.5)

802/1311 (61.2)

637/1311 (48.6)

Stratified by type of ART regimen

   

NNRTI-based

    
 

For patients with HIV VL

583/740 (78.8)

603/784 (76.9)

503/711 (70.7)

 

Best-case scenario

830/987 (84.1)

806/987 (81.7)

779/987 (78.9)

 

Worst-case scenario

583/987 (59.1)

603/987 (61.1)

503/987 (51.0)

PI-based

   
 

For patients with HIV VL

171/240 (71.3)

199/270 (73.7)

134/227 (59.0)

 

Best-case scenario

255/324 (78.7)

253/324 (78.1)

231/324 (71.3)

 

Worst-case scenario

171/324 (52.8)

199/324 (61.4)

134/324 (41.4)

Stratified by calendar year of ART initiation

   

2000-2004

    
 

For patients with HIV VL

157/252 (62.3)

188/297 (63.3)

171/287 (59.6)

 

Best-case scenario

297/392 (75.8)

283/392 (72.2)

276/392 (70.4)

 

Worst-case scenario

157/392 (40.1)

188/392 (48.0)

171/392 (43.6)

2005-2010

    
 

For patients with HIV VL

597/728 (82.0)

614/757 (81.1)

466/651 (71.6)

 

Best-case scenario

788/919 (85.7)

776/919 (84.4)

734/919 (79.9)

 

Worst-case scenario

597/919 (65.0)

614/919 (66.8)

466/919 (50.7)

  1. HIV: human immunodeficiency virus, VL: viral load, PI: protease inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitor.
  2. aBest-case scenario assumes missing viral load data as suppression.
  3. bWorst-case scenario assumes missing viral loads data as failures.